In a filing, Tarsus Pharmaceuticals Inc revealed its President/CEO and Board Chair Azamian Bobak R. unloaded Company’s shares for reported $0.32 million on Mar 18 ’24. In the deal valued at $30.60 per share,10,415 shares were sold. As a result of this transaction, Azamian Bobak R. now holds 26,456 shares worth roughly $0.92 million.
Then, Neervannan Seshadri sold 4,879 shares, generating $149,297 in total proceeds. Upon selling the shares at $30.60, the Chief Operating Officer now owns 64,767 shares.
Before that, Mottiwala Aziz sold 4,766 shares. Tarsus Pharmaceuticals Inc shares valued at $145,840 were divested by the Chief Commercial Officer at a price of $30.60 per share. As a result of the transaction, Mottiwala Aziz now holds 54,075 shares, worth roughly $1.89 million.
Goldman initiated its Tarsus Pharmaceuticals Inc [TARS] rating to a Neutral in a research note published on November 20, 2023; the price target was $19. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in mid July with a ‘”an Outperform”‘ rating. Guggenheim began covering TARS with “Buy” recommendation on May 18, 2023. Barclays started covering the stock on August 01, 2022. It rated TARS as “an Overweight”.
Price Performance Review of TARS
On Tuesday, Tarsus Pharmaceuticals Inc [NASDAQ:TARS] saw its stock fall -0.11% to $34.90. Over the last five days, the stock has lost -3.75%. Tarsus Pharmaceuticals Inc shares have risen nearly 72.35% since the year began. Nevertheless, the stocks have risen 201.64% over the past one year. While a 52-week high of $40.40 was reached on 02/28/24, a 52-week low of $11.33 was recorded on 01/05/24. SMA at 50 days reached $33.50, while 200 days put it at $22.04. A total of 0.46 million shares were traded, compared to the trading of 0.39 million shares in the previous session.
Levels Of Support And Resistance For TARS Stock
The 24-hour chart illustrates a support level at 34.03, which if violated will result in even more drops to 33.15. On the upside, there is a resistance level at 36.17. A further resistance level may holdings at 37.44. The Relative Strength Index (RSI) on the 14-day chart is 51.45, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.35, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 73.25%. Stochastics %K at 38.69% indicates the stock is a holding.
The most recent change occurred on December 21, 2021 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
